References
- 1. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229.
- 2. Praet M, Pollakis G, Goormaghtigh E, Ruysschaert JM. Damages of the mitochondrial membrane in Adriamycin treated mice. Cancer Lett. 1984;25:89-96.10.1016/S0304-3835(84)80030-0
- 3. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 2001;61:771-7.
- 4. Arai M, Tomaru K, Takizawa T, Sekguchi K, Yokoyama T, Suzuki T, et al. Sarcoplasmic reticulum genes are selectively down-regulated in cardiomiopathy produced by doxorubicin in rabbits. J Moll Cell Cardiol. 1998;30:243-54.
- 5. Gambliel HA, Burke BE, Cusack BJ, Walsh GM, Zhang YL, Mushlin PS, et al. Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. Biochem. Biophys. Res. Commun. 2002;291:433-8.
- 6. Jensen RA. Doxorubicin cardiotoxicity: contractile changes after long-term treatment in the rat. J. Pharmacol. Exp. Ther. 1986;236:197-203.
- 7. Ryan T, Sharma P, Ignatchenko A, MacLennan DH, Kislinger T, Gramolini AO. Identification of novel ryanodine receptor 1 (RyR1) protein interaction with calcium homeostasis endoplasmic reticulum protein (CHERP). J. Biol. Chem. 2011;286(19):17060–8.
- 8. Dudka J. Rola reaktywnych form tlenu i azotu w zaburzeniach komórkowej homeostazy wapnia i żelaza w kardiotoksyczności antracyklinowej. Postepy Hig Med Dosw. 2006;60:241-7.
- 9. Vangheluwe P, Wuytack F. Improving cardiac Ca2+ transport into the sarcoplasmic reticulum in heart failure: lessons from the ubiquitous SERCA2b Ca2+ pump. Biochem Soc Trans. 2011;39:781–7.
- 10. Arbabian A, Brouland JP, Gélébart P, Kovàcs T, Bobe R, Enouf J, et al. Endoplasmic reticulum calcium pumps and cancer. Biofactors. 2011;37(3): 139-49.
- 11. Olson RD, Gambiel HA, Vestal RE, Shadle SE, Charlier HAJr, Cusack BJ. Doxorubicin cardiac dysfunction: Effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine. Cardiovasc. Tox. 2005;05:269-83.
- 12. Korga A, Dudka J, Burdan F, Sliwinska J, Mandziuk S, Dawidek-Pietryka K. The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and Doxorubicin. Oxid Med Cell Longev. 2012;681367.
- 13. Szuławska A, Czyż M. Molekularne mechanizmy działania antracyklin. Postepy Hig Med. Dosw. 2006;60:78-100.
- 14. Ranek MJ, Wang X. Activation of the ubiquitin proteasome system in doxorubicin cardiomiopathy. Curr Hypertens Rep. 2009;11(6):389-95.10.1007/s11906-009-0068-8
- 15. Ondrias K, Borgatta L, Kim DH, Ehrlich BE. Biphasic effects of Doxorubicin on the calcium release channel from sarcoplasmic reticulum of cardiac muscle. Circulation Research. 1990;67:1167-73.
- 16. Kim SY, Kim SJ, Kim BJ, Rah SY, Chung SM, Im MJ, et al. Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in ratcardiomyocytes. Exp Mol Med. 2006;38(5):535-45.10.1038/emm.2006.63
- 17. Jamroziak K. Terapia nawrotowego i opornego szpiczaka plazmocytowego. Hematologia, 2011;2(1):116–30.
- 18. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, et al. Topoisomerase IIβ-mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67:8839-46.
- 19. Boucek RJJr, Miracle A, Anderson M, Engelman R, Atkinson J, Dodd DA. Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol. 1999;31(8):1435-46.